OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Bought by KBC Group NV

KBC Group NV raised its stake in shares of OraSure Technologies, Inc. (NASDAQ:OSUR) by 80.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 88,502 shares of the medical instruments supplier’s stock after purchasing an additional 39,469 shares during the period. KBC Group NV owned 0.15% of OraSure Technologies worth $1,991,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of OraSure Technologies by 6.9% in the second quarter. State Street Corp now owns 1,639,620 shares of the medical instruments supplier’s stock valued at $28,305,000 after acquiring an additional 106,326 shares in the last quarter. Federated Investors Inc. PA lifted its position in shares of OraSure Technologies by 505.6% in the second quarter. Federated Investors Inc. PA now owns 312,595 shares of the medical instruments supplier’s stock valued at $5,395,000 after acquiring an additional 260,977 shares in the last quarter. USA Financial Portformulas Corp lifted its position in shares of OraSure Technologies by 31.0% in the second quarter. USA Financial Portformulas Corp now owns 56,653 shares of the medical instruments supplier’s stock valued at $978,000 after acquiring an additional 13,421 shares in the last quarter. Chicago Equity Partners LLC lifted its position in shares of OraSure Technologies by 38.3% in the second quarter. Chicago Equity Partners LLC now owns 78,430 shares of the medical instruments supplier’s stock valued at $1,354,000 after acquiring an additional 21,730 shares in the last quarter. Finally, 361 Capital LLC lifted its position in shares of OraSure Technologies by 59.9% in the second quarter. 361 Capital LLC now owns 26,974 shares of the medical instruments supplier’s stock valued at $466,000 after acquiring an additional 10,107 shares in the last quarter. 94.43% of the stock is owned by institutional investors and hedge funds.

A number of research firms recently commented on OSUR. Zacks Investment Research downgraded OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Jefferies Group reiterated a “buy” rating and issued a $20.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 12th. Canaccord Genuity reiterated a “buy” rating and issued a $22.00 target price on shares of OraSure Technologies in a research report on Tuesday, September 19th. Finally, BidaskClub upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Thursday, December 21st. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $19.65.

In related news, Director Mara G. Aspinall acquired 5,000 shares of OraSure Technologies stock in a transaction on Tuesday, November 7th. The shares were bought at an average cost of $14.23 per share, with a total value of $71,150.00. Following the completion of the purchase, the director now directly owns 5,000 shares of the company’s stock, valued at approximately $71,150. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Douglas A. Michels sold 22,923 shares of the business’s stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $23.00, for a total value of $527,229.00. The disclosure for this sale can be found here. Insiders own 6.40% of the company’s stock.

Shares of OraSure Technologies, Inc. (NASDAQ:OSUR) traded up $0.43 during midday trading on Tuesday, reaching $19.29. The company’s stock had a trading volume of 793,009 shares, compared to its average volume of 927,156. OraSure Technologies, Inc. has a 52 week low of $8.39 and a 52 week high of $23.01. The company has a market capitalization of $1,170.00, a PE ratio of 37.10, a P/E/G ratio of 3.56 and a beta of 1.28.

OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.09 earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.09. OraSure Technologies had a return on equity of 14.12% and a net margin of 20.48%. The company had revenue of $42.30 million for the quarter, compared to analysts’ expectations of $40.87 million. During the same period in the previous year, the firm posted $0.11 earnings per share. The firm’s revenue for the quarter was up 31.0% on a year-over-year basis. research analysts expect that OraSure Technologies, Inc. will post 0.42 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “OraSure Technologies, Inc. (NASDAQ:OSUR) Shares Bought by KBC Group NV” was originally reported by TrueBlueTribune and is the property of of TrueBlueTribune. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://www.truebluetribune.com/2018/01/03/orasure-technologies-inc-osur-stake-increased-by-kbc-group-nv.html.

About OraSure Technologies

OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.

Institutional Ownership by Quarter for OraSure Technologies (NASDAQ:OSUR)

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply